THE Therapeutic Goods Administration has added three new medications to its list of designated orphan drugs.
The additions include lenvanitib capsules from Eisai Australia for the treatment of hepatocellular carcinoma; Emerge Health Australia's Disanit (nitisinone) for the treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1); and momelotinib dihydrochloride monohydrate from Gilead Sciences, indicated for the treatment of myelofibrosis.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Aug 17